Compare VPG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | ATAI |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 1.3B |
| IPO Year | 2010 | 2021 |
| Metric | VPG | ATAI |
|---|---|---|
| Price | $45.91 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $53.50 | $15.13 |
| AVG Volume (30 Days) | 219.8K | ★ 4.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $307,202,000.00 | $308,000.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $111.93 | ★ N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $18.57 | $1.15 |
| 52 Week High | $56.25 | $6.73 |
| Indicator | VPG | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 55.70 |
| Support Level | $44.01 | $3.60 |
| Resistance Level | $48.61 | $4.30 |
| Average True Range (ATR) | 2.64 | 0.20 |
| MACD | 0.51 | 0.04 |
| Stochastic Oscillator | 82.04 | 79.43 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.